Top Menu

NIDA Funds Research on Cocaine Addiction Drug


The National Institute on Drug Abuse (NIDA) has agreed to fund a midstage clinical trial of a cocaine-addiction drug called vigabatrin, produced by Catalyst Pharmaceutical Partners, Inc.

The Associated Press reported April 13 that NIDA will fund a second series of tests after a first clinical trial failed to find that the drug, CPP-109, had any effect on cocaine or methamphetamine users. Catalyst blamed the poor results on lack of compliance by study participants and said other findings indicated that the drug still has promise for treating cocaine addiction.

NIDA will pay $10 million for the new study, which will include 200 subjects. Catalyst will pay $2.8 million.

No responses yet.

Leave a Reply

Please read our comment policy and guidelines before you submit a comment. Your email address will not be published. Thank you for visiting

four + 3 =

Reproduction in whole or in part of this publication is strictly prohibited without prior consent. Photographic rights remain the property of Join Together and the Partnership for Drug-Free Kids. For reproduction inquiries, please e-mail